Ardsley Advisory Partners LP Pacira Bio Sciences, Inc. Transaction History
Ardsley Advisory Partners LP
- $612 Million
- Q2 2024
A detailed history of Ardsley Advisory Partners LP transactions in Pacira Bio Sciences, Inc. stock. As of the latest transaction made, Ardsley Advisory Partners LP holds 160,000 shares of PCRX stock, worth $2.75 Million. This represents 0.75% of its overall portfolio holdings.
Number of Shares
160,000
Previous 493,400
67.57%
Holding current value
$2.75 Million
Previous $14.4 Million
68.25%
% of portfolio
0.75%
Previous 2.17%
Shares
7 transactions
Others Institutions Holding PCRX
# of Institutions
277Shares Held
48.5MCall Options Held
378KPut Options Held
1.53M-
Black Rock Inc. New York, NY8.01MShares$138 Million0.01% of portfolio
-
Vanguard Group Inc Valley Forge, PA5.08MShares$87.4 Million0.0% of portfolio
-
Pacer Advisors, Inc. Malvern, PA2.16MShares$37.2 Million0.16% of portfolio
-
Jim Simons Renaissance Technologies LLC | New York, Ny2.07MShares$35.5 Million0.1% of portfolio
-
State Street Corp Boston, MA1.9MShares$32.7 Million0.0% of portfolio
About Pacira BioSciences, Inc.
- Ticker PCRX
- Exchange NASDAQ
- Sector Healthcare
- Industry Drug Manufacturers—Specialty & Generic
- Shares Outstandng 45,824,200
- Market Cap $787M
- Description
- Pacira BioSciences, Inc. provides non-opioid pain management and regenerative health solutions for healthcare practitioners and their patients in the United States. The company offers EXPAREL, a bupivacaine liposome injectable suspension; ZILRETTA, a triamcinolone acetonide extended-release injectable suspension; and iovera system, a non-opioid ...